Corporate News - 26 February 2021

Government decision to remove ban on UK-sourced plasma

Download PDF

26 February 2021

BPL welcomes the decision made by Government to lift the ban on UK plasma being used for the manufacture of immunoglobulins.

BPL is very supportive of this Government initiative which will result in plasma from UK blood donors being used to manufacture life-saving medicines, and will help the UK become self-sufficient in plasma supply.

Notes:

Department of Health and Social Care: Ban lifted to allow UK blood plasma to be used for life-saving treatments

https://www.gov.uk/government/news/ban-lifted-to-allow-uk-blood-plasma-to-be-used-for-life-saving-treatments

About Bio Products Laboratory (BPL)

Recognising the power of plasma and with many years of experience in the industry, BPL supplies high- quality plasma derived medicines to meet the needs of clinicians, patients and customers globally. Headquartered in the United Kingdom and with plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com

BPL consists of two operating divisions - BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors, in around 26 centres across the US. BPL Plasma employs over 900 staff, to support the needs of donors and to ensure high-quality plasma collection in all their centres. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follow industry guidelines. BPL Plasma operates clean and safe plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services and administrative activities. BPL’s plasma derived medicines are commercially available in the UK, USA and 30 plus other countries around the world through our network of local affiliates and distribution partners.